-transparent.png){kind=logo}
Seven women with hirsutism (five with polycystic ovarian disease, two with eumenorrheic hirsutism) were studied before and during the fourth and sixth cycles of oral contraceptive treatment (norethindrone/mestranol, 1 mg/0.05 mg). Plasma testosterone, androstenedione, and dehydroepiandrosterone sulfate were measured before and during treatment. Testosterone was reduced 72%, androstenedione was reduced 68.5%, and dehydroepiandrosterone sulfate was reduced 41.25% during therapy. Plasma dehydroepiandrosterone sulfate normalized in all patients with pretreatment elevation of this steroid. Norethindrone/mestranol, 1 mg/0.05 mg is capable of suppressing both ovarian and adrenal androgens in hirsute women with modest elevation of these steroids.
R H Wiebe, and
C V Morris
May 1978,
Obstetrics and gynecology,
R H Wiebe, and
C V Morris
January 1982,
European journal of clinical pharmacology,
R H Wiebe, and
C V Morris
September 1970,
Lancet (London, England),
R H Wiebe, and
C V Morris
March 1973,
Biomedicine / [publiee pour l'A.A.I.C.I.G.],
R H Wiebe, and
C V Morris
July 1990,
British journal of clinical pharmacology,
R H Wiebe, and
C V Morris
July 1983,
Contraception,
R H Wiebe, and
C V Morris
April 1982,
The Journal of clinical endocrinology and metabolism,
R H Wiebe, and
C V Morris
January 1978,
Journal of the Tennessee Medical Association,
R H Wiebe, and
C V Morris
March 1974,
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
